Modality
siRNA
MOA
IL-17i
Target
CD20
Pathway
mTOR
Schizophrenia
Development Pipeline
Preclinical
~Sep 2012
→ ~Dec 2013
Phase 1
~Mar 2014
→ ~Jun 2015
Phase 2
~Sep 2015
→ ~Dec 2016
Phase 3
~Mar 2017
→ ~Jun 2018
NDA/BLA
~Sep 2018
→ ~Dec 2019
Approved
Mar 2020
→ Aug 2028
ApprovedCurrent
NCT08915482
514 pts·Schizophrenia
2020-03→2028-08·Active
514 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2028-08-052.3y awayPh3 Readout· Schizophrenia
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Approved
Active
Catalysts
Ph3 Readout
2028-08-05 · 2.3y away
Schizophrenia
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08915482 | Approved | Schizophrenia | Active | 514 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| Nidaratamab | Krystal Biotech | Preclinical | RET |